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Cheyne-Stokes respiration (CSR) characterizes a pattern of cyclic oscillations of 
tidal volume and respiratory rate with periods of hyperpnea alternating with hypopnea or 
apnea in patients with heart failure. CSR harms the failing heart through intermittent 
hypoxia brought about by apneas and hypopneas and recurrent sympathetic surges. CSR 
impairs the quality of life and increases cardiac mortality in patients with heart failure. 
Thus, CSR should actively be pursued in patients with severe heart failure. When CSR 
persists despite optimal therapy of heart failure, non-invasive adaptive servo-ventilation 




 Sleep disordered breathing (SDB) is common in patients with congestive heart 
failure (CHF) and SDB is increasingly recognized as an independent risk factor for 
morbidity and mortality in these patients [1]. This review focuses on Cheyne-Stokes 
respiration (CSR), a pattern of waxing and waning of ventilation with periods of 
hyperpnea alternating with central apnea/hypopnea in heart failure patients. CSR is also 
observed in certain patients with cerebro-vascular strokes [2] and in patients with 
pulmonary hypertension [3]. Typical features of CSR,  the particular type of periodic 
breathing associated with heart failure, are a long duration of the hyperpnea phase and of 
the cycle time (figure 1) which are linked to the prolonged lung to chemoreceptor 
circulation time in low cardiac output states [4]. CSR is often observed during sleep and 
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is also termed central sleep apnea but CSR may as well emerge during wakefulness and 
even during physical activity [5] (Figure 1) [6,7]. Therefore, CSR in the context of 
chronic heart failure may be considered a syndrome distinct from other clinical 
conditions that are also associated with periodic central sleep apnea such as the idiopathic 
central sleep apnea syndrome or high altitude periodic breathing [8]. 
Since its first description in a patient suffering from heart failure with atrial fibrillation 
and a stroke two hundred years ago, CSR has been considered an ominous sign of the 
gravity of the underlying disease and as a forecast of the looming death. In the meantime, 
scientific evidence has accumulated to prove that CSR harms the failing heart. Quality of 
life and sleep as well as ventricular function suffer from frequent periodic breathing and 
CSR has been identified to shorten the life of heart failure patients. Pharmacological and 
non-pharmacological therapies are able to suppress or counteract CSR and treatment has 
been shown to improve ventricular function as well as quality of life [1,5]. Non-invasive 
ventilation, including continuous pressure support (CPAP), appears currently to most 
powerfully counteract CSR but the jury is still out if non-invasive ventilation may also 
prolong the life of heart failure patients. We reviewed the current literature on 
prevalence, risk factors, consequences and therapies of CSR in patients with CHF.  
 
 
Prevalence and Importance of Heart Failure and Cheyne-Stokes Respiration 
About 0.5% of the general population and 16% of people older than 75 years 
suffer from heart failure, respectively. Severe heart failure causes about 20% of all 
hospital stays in the elderly and carries a mortality of about 45% per year, which is higher 
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than for most cancers [9,10]. Sleep apnea often accompanies and aggravates heart failure. 
The reported prevalence of sleep-disordered breathing (either central or obstructive sleep 
apnea) varies largely due to differences in patient selection and methodological issues. 
Most studies recruited outpatients from heart failure clinics, but some included 
hospitalized patients and the severity of heart failure, assessed either by 
echocardiography or clinically, varied widely. The apnea-hypopnea index (AHI) that 
defined sleep apnea ranged from 15 to 5/h and, accordingly, the prevalence varied from 
47 % to 82% and from 21% to 66% for sleep disordered breathing and CSR in patients 
with CHF, respectively [2,3,11-21] (Figure 2). Thus, CSR is not limited to severe heart 
failure but may also occur at moderate stages of CHF with left ventricular ejection 
fraction between 35% and 45% with milder functional impairment (NYHA II). Although 
many studies reported a predominance of CSR in CHF patients, OSA was also quite 
common [22]. (Figure 2) 
 In addition to left ventricular failure, CSR is also associated with right heart 
failure secondary to pulmonary hypertension [3] [23] and with cerebro-vascular stroke 
[2,24,25]. The highest prevalence of CSR occurred in hospitalized patients with severe 
CHF and/or stroke [2,5,26,27] (Figure 2). 
 
Risk Factors for CSR 
Oldenburg et al [20] recently screened 700 patients with CHF referred to a 
cardiology division for sleep apnea. Among those with a left ventricular ejection fraction 
(LVEF) of <40%, 40% had CSR/CSA. As compared to those without SDB, patients with 
CSR/CSA were slightly older, predominantly male and had more severe CHF as reflected 
 4
in a higher NYHA functional class and a lower LVEF. Elevated pulmonary capillary 
wedge pressure (PCWP) is associated with hypocapnia, and both have been identified as 
risk factors for CSR [28,29]. In addition patients with CSR had a higher prevalence of 
atrial fibrillation and a reduced exercise capacity[20]. Mared et al.  [16] found age to be 
the most important risk factor for CSR. 
 
Consequences of CSR 
Patients with CHF are less physically active if CSR occurs [30]. In 22 patients 
with mild to moderate CHF, actimetry was recorded to monitor the circadian activity 
pattern over the course of 2 weeks. Half the patients had predominantly central sleep 
apnea. On average, patients with CHF and sleep apnea spent more time resting at night 
and were less active during the day. In addition, their sleep was frequently interrupted by 
movements presumably due to arousals associated with apneas [31]. 
CSR also impairs quality of life (QoL) in patients with CHF. Carmona-Bernal et al.  [32] 
evaluated patients with and without CSR with two QoL questionnaires. The Minnesota 
Living with Heart Failure questionnaire focuses on domains such as physical activity, 
fatigue, social relations and mood that are typically affected by CHF. The Functional 
Outcome of Sleep Questionnaire evaluates domains affected by sleep disorders such as 
productivity, activity and vigilance. Both questionnaires revealed impaired QoL for 
patients with CSR highlighting the clinical relevance of CSR [32]. 
We have recently evaluated QoL of patients with CSR associated with idiopathic 
pulmonary hypertension. Sleep studies in 38 consecutive patients identified 4 patients 
with predominant OSA and 15 patients with CSR (AHI>10 cycles/h). Patients with CSR 
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had impaired QoL mainly in the physical domain as assessed with the Minnesota 
questionnaire as well as with the generic SF-36 questionnaire. Remarkably, patients did 
not perceive subjective daytime sleepiness or other symptoms that would have clearly 
suggested sleep apnea [3]. 
Other studies have also confirmed that subjective sleepiness is not a prominent symptom 
of patients with CSR. Pepperell et al. [33] randomly treated 30 patients with CSR due to 
CHF either with therapeutic adaptive servo ventilation (ASV) or with a sham treatment 
during 1 months. The baseline Epworth sleepiness score was nearly normal in both 
groups and did not change with treatment. In contrast, ASV revealed an improvement in 
the sleep resistance time although several patients had normal sleep resistance time from 
the beginning. In conclusion, patients with CSR often seem not to perceive excessive 
sleepiness. 
Additionally, CSR increases sympathetic nervous activity (SNA) that harms the failing 
heart. Solin et al. [34] measured urinary catecholamines as a marker of SNA in patients 
with CHF (LVEF<35%), OSA and healthy controls. CHF patients excreted more 
norepinephrine than patients with OSA or healthy subjects; CHF patients with CSR 
excreted the most norepinephine. Multiple regression identified the severity of CHF as 
reflected by pulmonary capillary wedge pressure and nocturnal hypoxemia as strong 
predictors of urinary catecholamine levels. Elevated SNA may immediately impair 
ventricular function so that Brain Natriuretic Peptide (BNP) as a marker of CHF has also 
been found to increase during the night in patients with CHF and CSR [35,36]. 
Sympathetic activity is increased during the hyperpneic phase of CSR and the heart 
seems to be most vulnerable for arrhythmia during hyperpnea [37]. 24 h ECG monitoring 
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revealed that patients with severe CSR had a significantly increased prevalence of non-
sustained ventricular tachycardia and other arrhythmias as compared to patients with mild 
or no CSR [38]. In addition, patients with severe CSR had a reduced heart rate variability 
which suggests autonomic dysfunction [39]. A reduced percentage of beats with more 
than 50ms of RR interval variation was associated with mortality in HF patients in an 
earlier study [40]. 
 
Prognosis of patients with CSR and CHF 
Hanly et al. [41] reported a mortality of 86% and 56% in patients with heart 
failure and CSR compared to patients without CSR during a follow-up of 2 years, 
respectively. Javaheri et al. [42] recently found in a retrospective cohort study that both 
obstructive and central sleep apnea in heart failure patients were largely under diagnosed. 
Patients who were diagnosed and treated had a better 2-year survival than patients who 
were not tested (hazard ratio 0.33). The association of CSR with a two- to threefold 
increase in mortality sparked the hope that treatment of CSR would decrease mortality 
albeit other reports questioned an independent association of CSR and mortality in heart 
failure [19].  
Autonomic dysfunction and cardiac electrical instability are potential explanations for the 
increased mortality in CHF patients with CSR. Lanfranchi et al. [43] observed 62 patients 
with severe CHF for a median of 28 months. Multiple regression revealed left atrial area 
(LA) measured by echocardiography and the number of CSR cycles per hour at night to 
be the most important independent predictors of transplantation free survival. For 
example, the estimated mortality of a patient with a LA area of 55 cm2 and 40 cycles/h of 
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CSR was more than four times higher than the mortality of a patient with similar LA area 
but no CSR. (Table 1) summarizes the most recent studies of the impact of CSR on 
survival in HF patients who were treated with all current standard cardiac medications 
[43] [5,19,21,44-46]. The outcome was either death or cardiac transplantation. The 
majority of studies found an increased mortality with a hazard ratio of 2.1 to 5.7 for CSR 
with only two exceptions [19,21]. Patients and methods varied between studies, which 
may explain the different outcomes. For example, the AHI cut-off that discriminated 
patients with and without CSR varied between 5 and 30/h. The patients’ mean LVEF was 
very low with one exception and the observation time ranged from 2.2 yrs to more than 4 
years. Some studies excluded obese patients or those with atrial fibrillation and CSR was 
treated with oxygen or CPAP in three studies; two studies included daytime CSR. 
Corra et al. [45] studied patients with an EF<40% who underwent sleep studies as well as 
spiroergometry; patients were followed for a mean of 3 years. When controlled for 
clinical and echocardiographic severity of CHF, cumulative survival without cardiac 
events was most reduced in patients who had both CSR during the night and during 
exercise testing. 
CSR not only occurs during the night but also during the day. We recently found patients 
with severe heart failure to breathe periodically during about 10% of the daytime [5]. 
Continuous recordings of the breathing pattern in 60 patients with severe heart failure 
during their usual activities over 24 h at home revealed CSR to peak at 1pm, 5 pm and 3 
am (Figure 3). Daytime CSR was associated with a higher mortality while nighttime 
CSR was not an independent predictor of survival during the observation time of more 
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than two years. Patients with daytime CSR had a nearly 4-fold increased mortality even 
when controlled for age, gender and severity of heart failure.  
Although data from the majority of studies suggests an independent effect of CSR on 
mortality in CHF, the association is not always strong. One reason for the variable 
association may be the varying prevalence of CSR within the same patient. Of 19 patients 
monitored over the course of 4 successive nights, 8 revealed a change in the severity of 
apnea from mild to severe if a cut-off of 30/h was selected and 8 changed their 
predominant type of apnea from CSR to OSA and vice versa [47]. Moreover, some 
patients change their apnea type within the same night; while OSA may prevail in the 
first part of the night, CSR often dominates in the second part [48]. 
 
 
Pathophysiology of Cheyne-Stokes Respiration 
Left heart failure that causes an increased pulmonary venous pressure is regarded as a 
source of CSR. The elevated pulmonary venous pressure leads to pulmonary congestion 
that stimulates the pulmonary stretch receptors, which heighten the sensitivity of 
peripheral chemoreceptors for CO2 through their vagal afferents [28,49,50]. Since CO2 
sensitivity increases, patients begin to hyperventilate and the arterial CO2 (PaCO2) falls 
below the apnea threshold [51]. Moreover, the hypoxia that follows the apnea/hypopnea 
enhances the post-apneic hyperventilation. If chemical control prevails the cortical 
influence on the respiratory controller, as it typically occurs during sleep, patients 
become apneic until the PaCO2 rises again above the apnea threshold. Thus, the 
alternating pattern of apnea and hyperpnea continues due to oscillations of the PaCO2 
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around the apnea threshold [52,53]. This periodic respiratory over- and undershoot causes 
additional sympathetic stimulation in patients who are already sympathetically stimulated 
through their heart failure [54]. 
 Recent work confirmed the key role of CO2 in the patho-physiology of CSR that 
primarily seems to be determined by the difference of the PaCO2 during steady state 
ventilation (i.e., the eupneic PaCO2) and the respective apnea threshold for CO2 [55,56]. 
Patients with high ventilatory equivalents for CO2 during exercise testing were 
particularly prone to CSR because the heightened ventilatory equivalent was an indicator 
of the increased chemo sensitivity for CO2 [57].  The augmented chemo sensitivity is 
likely caused by the pulmonary congestion because the pulmonary capillary occlusion 
pressure is inversely correlated with the PaCO2 during wakefulness [28,49]. Since in 
about 20% of patients CSR persists in an albeit milder form up to 12 months after heart 
transplantation, periodic breathing appears to result not only from pulmonary congestion 
but part of the pattern seems to be learned and engraved in the respiratory controller 
[58,59]. It has also become obvious that obstructive and central apneas are not strictly 
different entities but may share a common origin because obstructive apneas may 
dominate the first half of the night transforming to mainly central apneas towards the 
morning in the same patient [47,48]; in addition, the first breath of hyperpnea often has 
an obstructive component during CSR [60]. 
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Therapy of Cheyne-Stokes Respiration 
Treatment of the underlying heart disease 
CSR fuels the vicious cycle of heart failure through recurrent sympathetic over 
stimulation and intermittent hypoxia so that the transformation of periodic into regular 
breathing has been a longstanding aim of cardiac therapy [61]. Primarily, the 
pharmacological and interventional therapies aim to ease pulmonary congestion through a 
decrease in preload and afterload e.g. with diuretics and ACE-inhibitors, to lessen 
sympathetic over stimulation through the blockade of 1-receptors, or to optimize cardiac 
output by electrical stimulation. Walsh et al. [62] found the ACE-inhibitor captopril to 
improve sleep apnea and sleep quality in heart failure patients. Carvedilol, a beta-blocker 
commonly used for the treatment of congestive heart failure, has been demonstrated to 
reduce CSR in patients with CHF [63]. Atrial overdrive pacing was reported to reduce 
CSR in patients with heart failure, but these results could not be reproduced by several 
consecutive studies [64-67]. Cardiac resynchronization with biventricular pacemakers has 
repeatedly been reported to more than halve CSR in patients with severe heart failure and 
ventricular asynchrony. Kara et al. [68] found a significant improvement of central sleep 
apnea under active stimulation with atrial synchronized biventricular pacemakers in 12 
patients with HF and left ventricular ejection fraction of 28 ± 2.8%. Cardiac 
resynchronization therapy has been shown to also improve sleep quality, quality of life as 
well as cardiac pump function and patients´ outcome. Therefore, this albeit very 
expensive therapy should be evaluated in patients with severe heart failure associated 
with ventricular asynchrony due to conduction abnormalities [69]. If the cardiac therapy 
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fails to reverse CSR, directly influencing the respiratory controller to smooth the periodic 
breathing arises as the goal of therapy [9,10,70]. 
 
Pharmacotherapy of CSR 
Theophylline increases the respiratory drive and improves myocardial 
contractility so that periodic breathing decreases, but at the same time the drug doubles 
the serum concentration of renin, causes arrhythmias and possibly increases the risk of 
sudden death [71]. In a randomized study including 15 patients, the treatment with 
theophylline over 5 days improved CSR but not cardiac pump function [72]. Andreas et 
al. [73] demonstrated that theophylline did not increase sympathetic nerve activity in 
heart failure patients in contrast to healthy controls, but plasma renin level doubled in 
both groups. Theophylline is therefore currently not recommended as a treatment of CSR. 
Acetazolamide is a carboanhydrase inhibitor that causes renal loss of bicarbonate. 
The resulting metabolic acidosis stimulates respiration and reduces periodic breathing by 
increasing the difference between the eupneic PaCO2 and the respective apnea threshold. 
In a short randomized trial of 12 patients with heart failure, acetazolamide decreased 
periodic breathing by 38% and improved daytime sleepiness [56], but since long-term 
results are lacking, the drug may only be tried in selected patients under careful 
supervision.   
Respiratory disturbances might be aggravated by arousals which destabilize 
ventilation. In order to suppress arousals, Younes et al. applied pentobarbital in a 
placebo-controlled animal trial [74]. However, the authors found serious blood gas 
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alterations with prolonged hypoxia. Data on the suppression of arousals in humans are 
not yet available. 
 
Oxygen and Inhalation of Carbon Dioxide 
Supplemental oxygen increases the oxygen supply of the left ventricle and 
additionally may reduce the reflex activation of the peripheral chemoreceptors. Oxygen 
suppresses periodic breathing because it blunts the hypoxic respiratory drive and the 
consecutive hyperventilation. However, data from clinical studies show conflicting 
results. Thus, nocturnal oxygen applied over 1 to 4 weeks cut CSR by half, decreased 
nocturnal norepinephrine excretion and increased maximal oxygen uptake during 
exercise because of improved physical performance [75-78]. Conversely, Gold et al. [79] 
found that supplemental oxygen may increase frequency of obstructive apnoeas in 
patients with mixed sleep apnea. Moreover, left ventricular ejection fraction and the 
patients’ quality of life did not improve [75,77,78,80]. In contrast, recent studies also 
found nocturnal oxygen to improve quality of life and cardiac function in heart failure 
patients [81,82].  The CANPAP post hoc-analysis showed that optimal suppression of 
respiratory disturbances is crucial to lessen mortality in heart failure patients with sleep-
related breathing disturbances [83]. Since bilevel pressure support ventilation or adaptive 
servo-ventilation have been found to suppress CSR better than oxygen [84] oxygen may 
be reserved for patients who cannot tolerate non-invasive ventilation. 
Inhalation of supplemental CO2 or addition of artificial dead space suppresses 
CSR through a permanent elevation of PaCO2 above the apnea threshold [85-88]. In a 
recent trial including 6 patients without heart failure, Thomas et al. [89] found the 
 13
addition of computer controlled CO2 at an inspiratory concentration of 0.5 to 1% through 
a CPAP circuit very effective for the treatment of CSR. Since increased PaCO2 can cause 
sympathetic stimulation and because trials of long-term effects of CO2-augmentation are 
lacking, this therapy remains experimental [90]. The disadvantage of permanently 
elevated PaCO2 could eventually be overcome by dynamical application of low 
inspiratory concentration of CO2 as recently shown by Mebrate et al. [91] in a 
sophisticated computer model. 
 
Positive airway pressure ventilation 
Over the past ten years, the application of continuous positive airway pressure 
(CPAP) has repeatedly been shown to reduce CSR, to improve left ventricular function 
and to decrease nocturnal norepinephrine excretion in patients with heart failure [92-94]. 
CPAP increases the intrathoracic pressure, which decreases both the afterload by 
lowering transmural cardiac pressure and the preload by lowering the venous return, so 
that cardiac function improves in patients with high ventricular filling pressures [95-97].  
Additionally, CPAP may interrupt CSR by counteracting the periodic oscillations of the 
end-expiratory lung volume during CSR [98]. In a randomized trial with 66 patients over 
5 years, CPAP improved left-ventricular ejection fraction by 7% and decreased the 
combined rate of mortality and transplantation in the group of 29 patients with CSR while 
the 37 patients without CSR did not benefit from CPAP [44]. Based on these results, a 
large randomized multicenter trial containing 258 patients with heart failure and CSR was 
performed in Canada (CANPAP) [99]. 128 patients were treated with CPAP and were 
compared to 130 matched patients without CPAP therapy. CPAP reduced CSR, improved 
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nocturnal oxygen saturation, enhanced left-ventricular ejection fraction by 2%, reduced 
nocturnal norepinephrine excretion and also prolonged 6 min walking distance. Despite 
all these advantages of CPAP therapy, the treated patients had a lower transplant-free 
survival compared to untreated patients during the initial 18 months of the trial; after 18 
months, survival rate was similar for both groups. The trial was precociously terminated 
because of the higher mortality of treated patients while mortality of untreated patients 
and patient recruitment was unexpectedly low. The converse effect of CPAP on mortality 
compared to the promising pilot study was explained by the improved pharmacological 
treatment of heart failure in the past years. The addition of beta-blockers that has become 
a mainstay of heart failure therapy in the period in-between the pilot study [44] and the 
CANPAP trial [99] may have weakened the harmful influence of CSR and its 
consecutive sympathetic over stimulation on the failing heart. Other reasons for the 
divergent results of the CANPAP trial compared to the preceding study may be the lower 
compliance of patients with CPAP (4.3 vs. 5.6 h/d), the lower CPAP pressure (8 vs. 10 
cmH2O) and the lack of statistical power of the CANPAP trial because of the unforeseen 
low mortality of the control group [70]. In a post-hoc analysis, only the subgroup of 
patients in whom CPAP suppressed CSR successfully (AHI<15/h) benefited with 
increased left ventricular function and transplant free survival compared to patients who 
responded insufficiently (AHI>15/h) so that only good responders may profit from CPAP 
[83]. As a result of the CANPAP trial, CPAP cannot anymore be regarded as the standard 
therapy of CSR, but CPAP may still be beneficial for a subgroup of patients with high 
(>12 cmH2O) left-ventricular filling pressure and without atrial fibrillation [100,101]. As 
CPAP has been shown to improve survival in responders, a CPAP trial seem a reasonable 
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first step of ventilatory support for heart failure patients with CSR. However, this trial 
should closely be monitored and ASV should be used if CPAP fails.  
The disputed benefit of CPAP for the treatment of CSR and the patients’ 
problems with CPAP compliance has spawned interest in alternative modes of non-
invasive ventilation. While CPAP maintains the same pressure level during expiration 
and inspiration, pressure support ventilation (PSV) operates on a lower pressure during 
expiration and a higher pressure that actively supports inspiration. Contrary to CPAP, 
pressure support ventilation has the option to ventilate the patient during apnea and to 
support the respiration during hypopnea. Pressure support ventilation can be applied in 
different algorithms for the treatment of CSR: bilevel positive airway pressure (BPAP) in 
spontaneous (S) or timed (T) or spontaneous/ timed (ST) mode, and adaptive servo-
ventilation (ASV)  
Bilevel positive airway pressure modes apply a constant pressure support during 
inspiration. BPAP S only supports the patient´s spontaneous ventilation while BPAP T or 
ST apply mandatory breaths in case of breathing pauses. Therefore, BPAP ST or T 
actively ventilate the patient if his own ventilation is insufficient. They represent modes 
of non-invasive ventilation. Adaptive servo-ventilation (also named auto servo-
ventilation or anticyclic modulated ventilation) supports inspiration minimally during 
hyperpnea and maximally during apnea/hypopnea so that based on sophisticated 
algorithms the pressure support acts anti-cyclically to the cycles of CSR. The expiratory 
pressure is manually or automatically titrated in order to eliminate obstructive breathing 
disturbances. Similar to BPAP ST/T, ASV devices also apply mandatory breaths in case 
of apnoeas [102].  
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In a couple of small studies, BPAP ventilation in ST mode was somewhat better in 
suppressing CSR than CPAP [51,103]. Köhnlein et al. compared the efficacy of BPAP ST 
with CPAP in a cross-over study for two weeks each with a two weeks wash-out period 
in-between in patients with CSA and chronic congestive cardiac failure. Both modes 
improved respiratory disturbances, subjective and objective parameters of sleep quality 
and also left ventricular function with no significant difference between them [51]. Dohi et 
al. applied BPAP ST to a small group of patients who did not sufficiently respond to 
CPAP [104]. The authors showed a further reduction of respiratory disturbances in nine 
subjects. In contrast, Johnson et al. found that bilevel in ST or T mode was more likely to 
worsen than improve central breathing disturbances, including CSR [105]. As the body of 
evidence on bilevel therapy is very limited and the results are conflicting BPAP cannot 
generally be suggested for treatment of CSR.  
  
Compared to CPAP and BPAP, ASV more powerfully suppressed CSR; at the 
same time, sleep quality, quality of life, left ventricular function, and exercise capacity 
improved with ASV and norepinephrine excretion were suppressed [33,84,106-109]. 
Teschler et al. compared oxygen, CPAP, BPAP ST and ASV for one night each in a 
group of 14 patients [84]. Although BPAP ST showed a better improvement of the mean 
cental apnoea index (CAI) as compared to oxygen and CPAP, the individual results 
varied widely. In contrast, ASV normalised the CAI in almost all patients. Peperell et al. 
applied effective or sub-therapeutical ASV for one month in 30 patients with chronic 
heart failure and mainly CSR/CSA [33]. Effective ASV was superior in improving 
respiratory disturbances, daytime performance, cardiovascular and sympathetic markers. 
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Philippe et al. proved that ASV was superior to CPAP in terms of respiratory 
disturbances, heart function, quality of life, and compliance over 6 months [106]. In 
addition, Morgenthaler et al. showed that ASV was superior to BPAP ST in a 
heterogenous population of patients with CSA/CSR, complex sleep apnea and mixed 
sleep apnea [107]. ASV was also able to suppress CSR below 15 cycles/h in heart failure 
patients who remained refractory under CPAP and BPAP ventilation [110].  
In clinical practice, many patients suffer from co-existing obstructive sleep apnea 
and CSR/CSA rather than pure CSR/CSA. In two prospective observational studies two 
different algorithms of ASV proved to effectively suppress all types of respiratory 
disturbances and to improve sleep quality as measured by sleep stages and arousals with 
no difference between patients with and without cardiovascular diseases [111,112]. Kasai 
et al. confirmed these results in a CPAP controlled trial over three months in 31 heart 
failure patients [113]. Since patients with CSR infrequently suffer from daytime 
sleepiness, compliance with positive pressure therapies is often low and therefore the 
finding that compliance with ASV was 2h/d higher than with CPAP is very important 
[106]. However, it seems crucially important to focus on problems with mask and 
interface. Pusalavidyasagar et al. described a higher prevalence of interface problems in 
patients with complex sleep apnoea [114]. Active or passive closure of the upper airways 
can be supposed if an increase of the pressure support is not able to overcome breathing 
disturbances [60]. These phenomena should be primarily considered in case of treatment 
failure with ASV [102,112]. 
Although preliminary data from a CPAP-controlled trial over twelve months in 
patients with heart failure showed a significantly greater improvement of central 
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breathing disturbances with ASV [115] large studies on survival and cardiovascular 
outcomes are lacking. Nevertheless, ASV currently appears to be the most promising 




CSR is highly prevalent and harmful for patients with CHF. Since the treatment of 
CSR has been shown to improve cardiac function and quality of life, sleep studies should 
be performed and treatment for CSR ought to be tried in patients with severe heart 
failure. Albeit the proof that treatment of CSR lowers mortality is pending, CSR should 
be treated to fight the debilitating symptoms of severe heart failure. Currently, adaptive 
servo-ventilation seems to be the most efficient therapy for CSR.  Large randomized 
controlled trials of the long-term effects of ASV on morbidity and mortality in patients 
with severe heart failure and CSR are under way and their results are expected in the 
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Figure 1: Breathing pattern recorded in an ambulatory patient with severe heart failure 
by a portable device incorporating respiratory inductive plethysmography, pulse 
oximetry, ECG and an accelerometer. The left panel shows a period of walking, the right 
panel a period of quiet rest during daytime. Waxing and waning of the rib cage and 
abdominal excursions and of the minute ventilation derived from the calibrated 
inductance sensors reveal periodic breathing with subtle oscillations in oxygen saturation 
(SpO2). Modified from Brack et al. [5]. 
 
Figure 2: Prevalence of sleep apnea in patients with congestive heart failure, stroke or 
pulmonary hypertension and in a community sample of men older than 65 years. The data 
were retrieved from studies published by various authors indicated on the corresponding 
bars. Hatched and open columns represent the relative proportion of Cheyne-Stokes 
respiration/central sleep apnea (CSR/CSA) and of obstructive sleep apnea (OSA) , 
respectively. The cut-off levels of the apnea/hypopnea index (AHI) used for definition of 
sleep apnea are indicated. Severe congestive heart failure was defined by a left 
ventricular ejection fracture of less than 55 to 45%. In this group of patients, the 
prevalence of sleep apnea is very high (between 47% to 82%) due to a high prevalence of 
both, Cheyne-Stokes respiration and obstructive sleep apnea. 
 
Figure 3: Using portable monitoring devices in 60 ambulatory patients with severe 
congestive heart failure, the circadian prevalence of Cheyne-Stokes respiration was 
investigated. The highest number of Cheyne-Stokes breathing cycles occurred during the 
 38
night but Cheyne-Stokes respiration was also observed during daytime when patients 
were upright performing their usual daily activities. Patients with a high prevalence of 
daytime Cheyne-Stokes respiration (>10% of the daytime) had a much shorter survival 
without heart transplantation compared to patients with <10% of daytime with Cheyne-










Table. Prognostic significance of Cheyne-Stokes respiration in patients with 
heart failure 


















62 66 133 88 60 78 128 
Outcome death, Tx death, Tx death, Tx death death, Tx death death 
Risk associated 












presence of CSR, 
1/h 




23 22 23 24 26 20 36 
Mean observation 
period, y 



















* hazard ratio controlled for several confounders, with + and - denoting increased mortality and  equal 
mortality of CSR vs. no CSR, respectively, Tx = survival without cardiac transplantation 
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